Directory
Portfolio companies.
34,000+ PE-backed.
Active investments and exits across European private equity portfolios.
Filter by sector, geography, status. Find the right deal comp in seconds.
Active deals
241
currently held
Exits tracked
163
hand-checked
Sectors covered
1
across the portfolio
Countries covered
36
from every market
Latest activity
BP Technology VenturesadminDirector Departure · Resignation of MORELAND, Jennifer Lynne (director) · director resigned · governance change5 days agoDirector Departure · Resignation of MORELAND, Jennifer Lynne (director) · director resigned · governance change
adminB.P. Marsh & PartnerscapitalCapital Event · capital-return-purchase-own-shares-treasury-capital-date · Capital structure change5 days agoCapital Event · capital-return-purchase-own-shares-treasury-capital-date · Capital structure change
capital
Arkea CapitaladminBoard change · Management board member change:: TRIDEAU Thomas, Jérôme · Change in the management board6 days agoBoard change · Management board member change:: TRIDEAU Thomas, Jérôme · Change in the management board
adminCaledonia InvestmentscapitalCapital Event · capital-cancellation-shares · Capital structure change6 days agoCapital Event · capital-cancellation-shares · Capital structure change
capitalCervinvest CapitaladminCEO change · Appointment of CEO De Jongh, Guillaume · New CEO appointed1 week agoCEO change · Appointment of CEO De Jongh, Guillaume · New CEO appointed
adminCervinvest CapitaladminChairman change · Appointment of Chairman Radix, Maxence. Departure of CEO Rouland, Antoine · New Chairman appointed. CEO departure · leadership transition underway1 week agoChairman change · Appointment of Chairman Radix, Maxence. Departure of CEO Rouland, Antoine · New Chairman appointed. CEO departure · leadership transition underway
admin330 companies matching · Page 1 of 7
AMW
SHS VI
GermanySector
Pharma
InvestorSHS Gesellschaft für Beteiligungsmanagement
Entry
2014
Hold
12yr
Owners
4
Galderma
Ardian Co-Investment Fund V
SwitzerlandSector
Pharma
InvestorArdian
Entry
2019
Hold
7yr
Owners
3
STADA Arzneimittel
CM-CIC Debt Fund 2
GermanySector
Pharma
InvestorCIC Private Debt
Entry
2017
Hold
9yr
Owners
3
Omnicare
Equistone Partners Europe Fund VI
USASector
Pharma
InvestorEquistone Partners Europe
Entry
2019
Hold
7yr
Owners
2
Exit
2026
to Allianz ambulante Onkologie
SWIXX BioPharma
Mérieux Participations 3
Europe
Sector
Pharma
InvestorMerieux Equity Partners
Entry
2021
Hold
5yr
Exit
2026
to SK Capital / Bain Capital Life Sciences
VISUfarma
GHO Capital Fund I LP
UKSector
Pharma
InvestorGHO Capital
Entry
2016
Hold
10yr
Exit
2026
to Lupin
Allderma
3iM Equity Partners
SwedenSector
Pharma
Investor3iM
Entry
2020
Hold
6yr
Exit
2026
to Avia Pharma (Impilo)
itm (ITM)
Capmont Private Equity
GermanySector
Pharma
InvestorCapmont
Entry
2018
Hold
8yr
Exit
2026
to Telix Pharmaceuticals Limited
Ceva
MED Rise
FranceSector
Pharma
InvestorARCHIMED
Entry
1999
Hold
16yr
Owners
16
Olyos
LFPI Capital
FranceSector
Pharma
InvestorLFPI GESTION
Entry
2018
Hold
7yr
Owners
3
Ceva Sante Animale
MED II
FranceSector
Pharma
InvestorARCHIMED
Entry
2025
Hold
1yr
Owners
2
Dec Group
capiton VI
SwitzerlandSector
Pharma
Investorcapiton
Entry
2020
Hold
5yr
Owners
2
HTBA
Miura Fund III
SpainSector
Pharma
InvestorMiura Partners
Entry
2019
Hold
6yr
Owners
2
Nuzoa
PAI Mid-Market Fund
SpainSector
Pharma
InvestorPAI Partners
Entry
2020
Hold
5yr
Owners
2
Theravia
Mérieux Participations 2
Europe
Sector
Pharma
InvestorMerieux Equity Partners
Entry
2018
Hold
7yr
Exit
2025
to Norgine
Neopharmed Gentili
NB Renaissance Fund III
ItalySector
Pharma
InvestorRenaissance Partners
Entry
2018
Hold
7yr
Owners
3
DMX Pharma
Fondo Italiano Private Equity Co-Investimenti (FIPEC)
ItalySector
Pharma
InvestorFondo Italiano d'Investimento SGR
Entry
2022
Hold
3yr
Owners
2
Provell Pharmaceuticals
Flerie Invest
United StatesSector
Pharma
InvestorFlerie
Entry
2013
Hold
12yr
Exit
2025
Sifi
21 Investimenti II
ItalySector
Pharma
Investor21 Invest
Entry
2010
Hold
15yr
Exit
2025
to Faes Farma
Cinclus Pharma
Claret European Growth Capital Fund IV
SwedenSector
Pharma
InvestorClaret Capital Partners
Entry
2022
Hold
2yr
Owners
3
ProductLife Group
Oakley Capital Fund V
FranceSector
Pharma
InvestorOakley Capital
Entry
2017
Hold
7yr
Owners
3
Aenova
BC European Capital IX
UKSector
Pharma
InvestorBC Partners
Entry
2005
Hold
12yr
Owners
2
Exit
2024
to Kuhne Holding
Biovian
ERES III
FranceSector
Pharma
InvestorElyan Partners
Entry
2018
Hold
8yr
Owners
2
Biose Industrie
Cathay Capital Small Cap III
FranceSector
Pharma
InvestorCathay Capital
Entry
2020
Hold
4yr
Exit
2024
to L-GAM / BPI France (French Tech Souveraineté)
Synthon
BC European Capital X
NetherlandsSector
Pharma
InvestorBC Partners
Entry
2019
Hold
5yr
Exit
2024
to Goldman Sachs Alternatives
Synerlab
Crédit Mutuel Equity
FranceSector
Pharma
InvestorCrédit Mutuel Equity
Entry
2007
Hold
11yr
Owners
4
Salfarm
Polaris Private Equity V
DenmarkSector
Pharma
InvestorPolaris
Entry
2020
Hold
4yr
Owners
2
APONTIS PHARMA
Paragon Fund II
GermanySector
Pharma
InvestorParagon Partners
Entry
2018
Hold
6yr
Exit
2024
to Zentiva
Content Group
Aksia Capital IV
ItalySector
Pharma
InvestorAksia SGR
Entry
2016
Hold
8yr
Exit
2024
to De Agostini
Deallus
MED I
United KingdomSector
Pharma
InvestorARCHIMED
Entry
2015
Hold
9yr
Exit
2024
to GlobalData Plc
GTP Bioways
Mérieux Participations 3
FranceSector
Pharma
InvestorMerieux Equity Partners
Entry
2019
Hold
5yr
Exit
2024
to Olon Group
Salpharm Holding ApS
Industri Udvikling V
DenmarkSector
Pharma
InvestorIndustri Udvikling
Entry
2020
Hold
4yr
Exit
2024
to Polaris Private Equity
Unither
IK Partnership Fund II
FranceSector
Pharma
InvestorIK Partners
Entry
1993
Hold
33yr
Owners
6
Cenexi
Indigo Capital I
FranceSector
Pharma
InvestorIndigo Capital
Entry
2008
Hold
9yr
Owners
3
Natac Group
Stellum Food & Tech I
SpainSector
Pharma
InvestorStellum Capital
Entry
2021
Hold
3yr
Owners
2
Acer Therapeutics
TVM Life Science Ventures
United StatesSector
Pharma
InvestorTVM Capital Life Science
Entry
2015
Hold
8yr
Exit
2023
to Zevra Therapeutics
Archimica
LIVIA Corporate Development
ItalySector
Pharma
InvestorLIVIA Group
Entry
2019
Hold
4yr
Exit
2023
to PI HealthSciences
Diater
Fondo Nazca Small Cap I
SpainSector
Pharma
InvestorNazca Capital
Entry
2019
Hold
4yr
Exit
2023
to WORG Pharma
EffRx Pharmaceuticals
Sobera Capital Fund IV
SwitzerlandSector
Pharma
InvestorSobera Capital
Entry
2018
Hold
5yr
Exit
2023
to Abiogen Pharma
Laboratoires Delbert
Vivalto Partners Fund I
FranceSector
Pharma
InvestorVivalto Partners
Entry
2022
Hold
4yr
Owners
5
Labomar
Charterhouse Capital Partners XI
ItalySector
Pharma
InvestorCharterhouse Capital Partners
Entry
2020
Hold
3yr
Owners
2
1.7x
Acino
Ardian Co-Investment Fund III
SwitzerlandSector
Pharma
InvestorArdian
Entry
2013
Hold
9yr
Owners
2
Exit
2022
to ADQ
CordenPharma
Astorg Mid-Cap
FranceSector
Pharma
InvestorAstorg
Entry
2006
Hold
16yr
Owners
2
Pharmalex
Auctus III
GermanySector
Pharma
InvestorAuctus Capital Partners
Entry
2014
Hold
8yr
Exit
2022
to Cencora (AmerisourceBergen)
Doc Generici
ICG Europe Mid-Market Fund I
FranceSector
Pharma
InvestorICG
Entry
2013
Hold
7yr
Owners
4
Kedrion
Permira VII
ItalySector
Pharma
InvestorPermira
Entry
2003
Hold
10yr
Owners
4
DOC Generici (ICG)
TPG Europe Portfolio
ItalySector
Pharma
InvestorTPG Europe
Entry
2019
Hold
4yr
Owners
2
IPS Specials
Mezzanine II
UKSector
Pharma
InvestorBeechbrook Capital
Entry
2010
Hold
12yr
Owners
2
Mipharm
Alto Capital V
ItalySector
Pharma
InvestorAlto Partners SGR
Entry
2016
Hold
6yr
Owners
2
The Ritedose Corporation
Novo Holdings Seed Investments
United StatesSector
Pharma
InvestorNovo Holdings
Entry
2017
Hold
5yr
Owners
2